Ipamorelin is a growth hormone-releasing peptide (GHRP) a completely different class
IGF-1 LR3 Clinical Evidence Context Direct human evidence on IGF-1 LR3 There are no published human clinical trials of IGF-1 LR3 itself
Understanding where retatrutide stands requires understanding what makes it mechanistically distinct from its predecessors, where Phase 3 trials currently sit, what a realistic regulatory timeline looks like, and what options exist for patients who cannot or do not want to wait
How many stack protocols does PDP publish
References Chew, BP, Park, JS, Wong, TS, Kim, HW, Weng, BBC, Bryne, KM, Hayek, MG, Reinhart, GA